Chipiron is a developer of advanced portable MRI machines that utilize cutting-edge quantum detectors to generate high-resolution three-dimensional anatomical images. By operating at ultra-low magnetic fields, these machines are designed to be lightweight and cost-effective, significantly reducing the price compared to traditional MRI systems. Chipiron's technology aims to enhance disease detection, diagnosis, and treatment monitoring, particularly for brain-related conditions, thereby assisting healthcare institutions in improving patient outcomes and potentially decreasing fatality rates associated with these ailments.
Astrape Networks
Grant in 2025
Astrape powers the future of datacenters: more bandwidth, less power.
VSORA
Venture Round in 2025
VSORA develops digital signal processing IP and chips for 5G networks, featuring a multicore DSP architecture that removes the need for DSP coprocessors and a shared DSP development flow that unites signal processing and software engineers in one environment to speed time-to-market. The company aims to boost DSP computing power while reducing power consumption, improving system performance, and shrinking silicon footprint. Based in France, founded in 2015 by veteran DSP engineers, VSORA serves chipmakers designing next-generation digital communications systems.
AMT Medical
Series B in 2025
AMT Medical B.V., established in 2015 and located in Ede, the Netherlands, specializes in the development of innovative medical devices for heart bypass surgery. The company's flagship product, the AMT Heart Bypass System, utilizes a minimal invasive technique known as the ELANA bypass, which was invented by neurosurgeon Prof. Dr. C.A.F. Tulleken and his research team. This advanced technology aims to enhance traditional heart bypass procedures by making them faster, safer, and less invasive, thereby improving patient outcomes and reducing complications. AMT Medical has completed the full development of its product and the production process, with all pre-clinical trials successfully concluded. The company is also preparing to initiate a clinical multi-center trial to further validate the technology's efficacy.
Sparrow Quantum
Series A in 2025
Sparrow Quantum specializes in developing deterministic single-photon sources for advancing light-matter interfaces in quantum technologies. With a focus on high efficiency, purity, indistinguishability, and outcoupling, the company's technology is based on over two decades of research at the Niels Bohr Institute.
FaradaIC Sensors
Seed Round in 2025
FaradaIC Sensors focuses on developing miniaturized gas sensors aimed at enhancing dioxygen detection capabilities for electronic devices. By employing standard microfabrication techniques, the company effectively reduces both the size and power consumption of its sensors, leading to lower production costs. This innovative approach allows for the commoditization of gas sensors, making them accessible and affordable for a variety of Internet of Things applications. FaradaIC Sensors is positioned to capitalize on the growing demand for flexible and cost-effective gas sensing solutions in the expanding IoT market.
BlueHeart Energy
Venture Round in 2025
BlueHeart Energy is a deep tech company focused on developing innovative green technologies to enhance heat pump performance. Utilizing thermoacoustics, the company generates sound waves within a closed circuit to produce heat and cold, marking a significant advancement as this technology is now being applied to residential heat pumps, previously limited to industrial applications. BlueHeart's products are designed to replace critical components in heat pumps, facilitating easy integration for original equipment manufacturers. The resulting heat pumps are versatile, silent, and cost-effective, suitable for both new and existing homes. Additionally, BlueHeart's technology is environmentally friendly, producing no CO2 emissions and eliminating the need for refrigerants, thus contributing to sustainable heating and cooling solutions.
Marvel Fusion
Series B in 2025
Marvel Fusion develops fusion energy technology using a laser-based reactor. Its innovative approach offers clean, safe, and reliable energy solutions, aiming to commercialize baseload fusion electrical power.
Brevel develops innovative cultivation technology for sustainable, low-cost production of microalgae. Its high-tech, indoor, automated systems use internal illumination to achieve over 90% cost reduction and up to 200 times higher yields compared to traditional methods. Brevel targets various markets where microalgae-derived products are in demand.
QuantWare
Series A in 2025
QuantWare is the global leader in quantum hardware, specializing in scalable quantum processors. It offers a unique 3D chip architecture that enables clients to build powerful quantum computers capable of tackling real-world challenges in fields like climate and life sciences.
Skyfora
Seed Round in 2025
Skyfora is a company focused on enhancing weather observation and forecasting capabilities through innovative technology. It addresses the limitations of traditional weather data by utilizing repurposed GNSS receivers located in telecom base stations, transforming them into advanced 4D weather scanners. This approach generates significantly more weather observation data, improving the accuracy and performance of AI-driven weather forecasts. Additionally, Skyfora develops forecasting software that leverages computer vision and IoT technologies to analyze high-resolution satellite images, particularly for predicting hurricanes. This technology aids disaster management efforts by providing critical insights that can help mitigate the impacts of severe weather events. Through its advancements, Skyfora contributes to global sustainability and enhances the operational efficiency of industries reliant on accurate weather information.
Precisionlife
Grant in 2025
Precisionlife employs a unique approach to drive innovation in chronic diseases through precision medicine. It uses artificial intelligence to generate deep insights into disease biology, stratifying patient populations for novel drug targets, biomarkers, and repositioning candidates.
Founded in Madrid, Spain in 2014, Wooptix develops innovative imaging technologies. The company specializes in creating three-dimensional modulation of images for enhanced volumetric photography and videography, enabling advanced image post-processing.
Stablepharma
Grant in 2025
Founded in 2012, Stablepharma specializes in developing processes for vaccine stabilization. Its flagship product, Stablevax, enables precise dosage pre-loading into syringes at manufacture, eliminating wastage. The company's technology platform converts existing vaccines and diagnostics into thermostable products, addressing global cold chain challenges.
MOA make healthy food for a sustainable world that solves growing global food demands. They are establishing a new industry of sustainable food that solves growing global food demands without the need for arable land. They are focused on designing high-value, natural and nutritious food.
MOA make healthy food for a sustainable world that solves growing global food demands. They are establishing a new industry of sustainable food that solves growing global food demands without the need for arable land. They are focused on designing high-value, natural and nutritious food.
Deeploy specializes in Machine Learning Operations (MLOps) software that enhances the accountability of AI models. Its core features include real-time monitoring, explainability tools, and compliance management, empowering organizations to maintain transparency and control over their AI systems.
ATMOS Space Cargo
Seed Round in 2025
ATMOS Space Cargo specializes in developing and manufacturing space capsules for returning cargo from space, facilitating microgravity experiments, and transporting commercial products. Its platform offers re-entry technology and services, enabling reliable and cost-effective delivery solutions for life sciences research, in-space manufacturing, and transportation industries.
QDI Systems B.V. is a startup based in Groningen, the Netherlands, focused on developing advanced imaging devices for medical applications using quantum dot technology. The company specializes in creating X-ray sensors that deliver high-contrast and high-resolution imaging, particularly for mammography, while also reducing radiation exposure for patients. QDI Systems aims to provide user-friendly quantum dot materials accompanied by comprehensive instructions for constructing high-performance imaging devices. By leveraging innovative technology, the company enhances the precision of medical imaging, enabling healthcare professionals to obtain critical diagnostic information efficiently and safely.
AlzeCure Pharma
Grant in 2025
AlzeCure Pharma is a Swedish pharmaceutical company dedicated to developing drug therapies targeting diseases affecting the central nervous system. Its primary focus lies in Alzheimer's disease, with five drug candidates at various stages of development.
QDI systems
Venture Round in 2025
QDI Systems B.V. is a startup based in Groningen, the Netherlands, focused on developing advanced imaging devices for medical applications using quantum dot technology. The company specializes in creating X-ray sensors that deliver high-contrast and high-resolution imaging, particularly for mammography, while also reducing radiation exposure for patients. QDI Systems aims to provide user-friendly quantum dot materials accompanied by comprehensive instructions for constructing high-performance imaging devices. By leveraging innovative technology, the company enhances the precision of medical imaging, enabling healthcare professionals to obtain critical diagnostic information efficiently and safely.
Elicera Therapeutics
Grant in 2025
Elicera Therapeutics is a clinical-stage immuno-oncology company based in Sweden that focuses on developing innovative cell and gene therapies to treat cancer. The company’s portfolio includes four drug candidates: two oncolytic virus therapies, ELC-100 and ELC-201, and two CAR T-cell treatments, ELC-301 and ELC-401. Additionally, Elicera has developed a universal CAR T-cell technology platform named iTANK (ELC-001), designed to enhance the efficacy of CAR T-cell therapies by enabling a multi-targeted approach against solid tumors. With its commitment to advancing immune-based cancer treatments, Elicera Therapeutics aims to improve outcomes for patients facing various forms of cancer.
Aplagon
Venture Round in 2025
Aplagon is a biopharmaceutical company focused on the development of innovative antithrombotic compounds aimed at addressing unmet medical needs in patients experiencing complications from vascular interventions. The company specializes in creating biological mimetics of heparin proteoglycan, which are designed to effectively manage thrombotic occlusions and ischemic reperfusion injuries associated with vascular injuries. By prioritizing safety and efficacy, Aplagon seeks to deliver antithrombotic therapies that offer significant advantages over existing treatments, ultimately improving patient outcomes in challenging medical scenarios.
TENSIVE s.r.l. is a biomedical company based in Milan, Italy, founded in 2012. It specializes in the development of innovative prostheses for natural breast reconstruction and augmentation. The company's products utilize biodegradable synthetic biomaterials and feature an internal micro-architecture that mimics blood vessel structures. These vascularized prostheses aim to enhance the quality of life for patients undergoing treatment for breast cancer, offering a solution that reduces the need for recurrent and costly surgical interventions. Through its focus on advanced biomaterials and design, TENSIVE seeks to provide effective and sustainable options for breast reconstruction.
Alcyon Photonics
Venture Round in 2025
Alcyon Photonics specializes in designing integrated photonic devices for managing light in various applications. Their core products are photonic IP building blocks and PIC management platforms, enabling broad use cases such as optical communications, biochemical sensing, and spectrometry.
.Lumen
Venture Round in 2025
Dotlumen is a research startup founded in 2020 and based in Cluj, Romania, focused on enhancing the quality of life for visually impaired individuals. The company develops innovative glasses equipped with a sensory and feedback system that aids users in navigating their environments. By leveraging advancements in artificial intelligence, robotics, and neuroscience, Dotlumen aims to empower blind individuals to better understand and interact with the world around them.
Photon IP is a Dutch deeptech company based in Eindhoven. It specializes in developing advanced photonics technologies for various applications.
AQLAS is shaping the quantum future and discovering Next-Gen Lasers redefining quantum computing. Our high-quality hardware is set apart by its economical, compact, and efficient nature, thus paving the way for the proliferation of quantum computers.
Right HeartWise
Pre Seed Round in 2025
Patient-specific right heart pumps that free patients from heavy battery packages and increase patient's quality of life.
Hervolution Therapeutics
Series A in 2024
Hervolution Therapeutics specializes in developing first-in-class immunotherapies targeting tumors by harnessing Human Endogenous Retroviral proteins (HERVs). The company pioneers innovative biotechnology solutions to combat hidden enemies within the human body.
ION-X is a technology company focused on developing advanced propulsion systems for small spacecraft. It specializes in electric propulsion technologies that utilize the ejection of fully ionized particles, offering high thrust and specific impulse (ISP). The company's innovative approach ensures long operational life and high modularity, making its solutions adaptable for various applications in the aerospace market. Additionally, ION-X aims to provide competitive production costs, facilitating mass production and meeting the increasing demand for efficient thrusters in the satellite industry.
GBM Works
Seed Round in 2024
GBM Works is a Netherlands-based company that develops offshore wind turbine foundation installation technologies. Founded in 2016 and based in The Hague, it focuses on methods for installing foundations with minimal environmental impact, including a silent installation approach designed to reduce noise pollution and disruption to marine life. The company's solutions aim to enable faster deployment of offshore wind projects while supporting sustainability goals in renewable energy.
FibriTech
Convertible Note in 2024
FibriTech develops a biomaterial technology producing sustainable, natural fiber-based materials for industrial and agricultural applications. Their products include eco-friendly alternatives to rock wool, glass wool, and foamed plastics, serving construction and horticulture sectors.
Acorai
Venture Round in 2024
Acorai develops a non-invasive heart failure monitoring platform centered around direct intracardiac pressure monitoring. Its patented technology combines sensor technologies and machine learning to enable accurate, cost-efficient care, reducing re-hospitalization and mortality rates.
Onward is a medical technology company focused on developing therapies aimed at enabling functional recovery for individuals with spinal cord injuries. The company is creating an Implantable Neuro-stimulation System (INS) that features real-time motion feedback and utilizes training tools for rehabilitation. Onward has developed two platforms for neurostimulation: ARCIM, an implantable system, and ARCEX, a non-invasive transcutaneous system. To establish its customer base, Onward has targeted the United States and four European markets, namely Germany, France, the United Kingdom, and the Netherlands.
AISPECO is a Lithuanian company specializing in geospatial monitoring systems for helicopters, planes, UAVs, and terrestrial vehicles.
Quantune Technologies
Grant in 2024
Quantune Technologies is a deep tech startup specializing in optics and photonics technology. The company focuses on developing advanced infrared spectrometers that facilitate continuous and non-invasive health monitoring. By miniaturizing traditional laboratory equipment used for molecular analysis into compact modules, Quantune enables both biomedical consumer devices and industrial applications. This innovation allows clients to efficiently conduct real-time monitoring and analysis of chemical compounds and emissions, providing accessible solutions for a range of novel applications.
Turing College
Grant in 2024
Turing College operates as an online educational institution specializing in data science. It offers courses suitable for individuals of varying skill levels and employs an income share agreement model, allowing students to defer payment until they secure employment. The college collaborates with tech companies to co-create its curriculum, providing these partners with real-time student performance updates to facilitate expedited hiring decisions.
Innoventric
Series B in 2024
Innoventric is an Israeli medical device company specializing in percutaneous solutions for Tricuspid Regurgitation and right heart disease. Founded in 2017, the company's flagship product is the Trillium™ technology, designed to treat Tricuspid Valve Regurgitation through functional valve replacement using Cross-Caval anchoring and a unique multi-valve design.
INBRAIN Neuroelectronics
Series B in 2024
INBRAIN Neuroelectronics is a medical device company based in Barcelona, Spain, founded in 2019. It specializes in developing graphene-based neural interfaces and intelligent neuromodulation systems aimed at treating brain disorders. The company has created the world's first graphene-based brain-computer interface (BCI) therapeutics platform, which integrates precise BCI decoding with micrometric modulation. This innovative technology allows for real-time monitoring and adaptive, personalized treatments for conditions such as Parkinson's disease, epilepsy, and stroke rehabilitation. By utilizing AI-driven solutions, INBRAIN maximizes therapeutic outcomes while minimizing side effects. The company is also expanding its capabilities through strategic partnerships, including collaborations with Merck KGaA and its subsidiary INNERVIA Bioelectronics, to explore applications in peripheral nerve and systemic diseases, advancing the field of neurotechnology and bioelectronics.
National University of Ireland, Maynooth
Grant in 2024
Maynooth University is internationally recognised for quality and value of Their research and scholarship and Their dedication and commitment to teaching and Their students.
Part of the NUI and formally established as an autonomous university in 1997, Maynooth University traces its origins to the foundation of the Royal College of St. Patrick in 1795, drawing inspiration from a heritage that includes over 200 years of education and scholarship. The University is a place of lively contrasts. It is a modern institution, dynamic, rapidly-growing, research-led and engaged, yet grounded in historic academic strengths and scholarly traditions.
Hideez Group
Grant in 2024
Hideez Group is a cybersecurity company that designs authentication devices and software to secure physical and logical access. It develops hybrid hardware and software solutions, including the Hideez Key, a wireless authentication and password-management device that also handles RFID credentials and digital signatures. The solution relies on encrypted Bluetooth, RFID, and NFC technologies, with proprietary encryption protocols and platform-agnostic compatibility to complement existing vendors. It provides passwordless identity management software that consolidates authentication workflows, using proximity sensing, one-time passwords, smart cards, and full-day authentication to improve security, compliance, and operational efficiency for organizations.
Sequentia Biotech
Series A in 2024
Founded in 2013 by Walter Sanseverino and Riccardo Aiese Cigliano, Sequentia Biotech is a bioinformatics company that transforms genomic data into actionable knowledge for academic research, plant/animal breeding, and biomedicine. With over 30 clients and partners, including public/private research centers, companies, and hospitals, Sequentia participates in more than 160 R&D projects and maintains two open-source biodata banks.
Ephos specializes in developing integrated photonic circuits using glass technology. Its focus is on minimizing signal loss and enabling innovative device designs for classical and quantum computing applications, communications, and sensing. The company's proprietary manufacturing process ensures high-quality production tailored to client needs in the computational infrastructure sector.
Reverion develops reversible, carbon-negative power plants using patented technology. Their containerized units achieve electrical efficiencies of up to 80%, doubling the electricity output of conventional gas engines while reducing greenhouse gas emissions and achieving a negative CO2 balance.
Treble Technologies is a company that focuses on advanced wave-based sound simulation products tailored for the architecture, engineering, and construction (AEC) industry. It offers specialized acoustics design software that enables the creation of physically accurate and perceptually realistic virtual acoustics. This software aids in minimizing risks and ensuring that designs adhere to all relevant regulations and certification standards. Additionally, it streamlines the process of importing, exporting, and reconfiguring models, ultimately saving time and costs for users. Treble's services find applications across various sectors, including automotive design, building architecture, immersive reality, and artificial intelligence, supporting studios and artists in delivering high-quality projects.
Wattalps is a technology company specializing in the development of lithium power systems tailored for small and medium-scale applications. Their product portfolio focuses on affordability, passive safety measures, efficient cooling mechanisms, extended lifespan, and robust cell protection features. Wattalps aims to simplify integration into vehicles or charging stations by offering standard and modular products, thereby facilitating swift, efficient, and cost-effective adoption of electric vehicle technologies and sustainable transportation solutions.
Oryl Photonics
Grant in 2024
Oryl Photonics specializes in developing laboratory instruments for pharmaceutical and biotech companies. Their core product provides a simple, reliable, and cost-effective method for measuring solubility, contributing to accelerated drug development and improved medicine. The company's unique technology preserves valuable substances during testing, offering a solubility measurement service that empowers researchers to make data-driven decisions and expedite product development.
Onego Bio
Venture Round in 2024
Onego Bio is a biotechnology company focused on producing animal-free egg white protein through precision fermentation. Their flagship product, Bioalbumen, offers a sustainable alternative to traditional egg proteins, boasting identical taste and nutritional profiles while providing superior functional properties and a significantly reduced environmental footprint. By employing commercially proven technology, Onego Bio meets the growing demand for stable and sustainable functional ingredients within the food industry. The company has gained recognition as a leader in innovation, winning Fast Company’s 2023 World Changing Ideas award. Additionally, Onego Bio is actively involved in the industry as a co-founder of the Precision Fermentation Alliance and Food Fermentation Europe, further establishing its commitment to advancing sustainable food solutions.
.Lumen
Venture Round in 2024
Dotlumen is a research startup founded in 2020 and based in Cluj, Romania, focused on enhancing the quality of life for visually impaired individuals. The company develops innovative glasses equipped with a sensory and feedback system that aids users in navigating their environments. By leveraging advancements in artificial intelligence, robotics, and neuroscience, Dotlumen aims to empower blind individuals to better understand and interact with the world around them.
MediWound Ltd. is an integrated biopharmaceutical company based in Yavne, Israel, that specializes in developing, manufacturing, and commercializing innovative therapeutic products for severe burns and chronic wounds. Founded in 2000, the company is known for its flagship product, NexoBrid, which is an FDA-approved biopharmaceutical designed for the removal of eschar in adults with deep partial- and full-thickness thermal burns, offering a less invasive alternative to surgical interventions. MediWound also advances other product candidates, including EscharEx, which has completed Phase II clinical trials for the debridement of chronic and hard-to-heal wounds, and MWPC003 for connective tissue disorders. The company aims to address significant unmet medical needs in these areas and improve patient outcomes.
MediWound Ltd. is an integrated biopharmaceutical company based in Yavne, Israel, that specializes in developing, manufacturing, and commercializing innovative therapeutic products for severe burns and chronic wounds. Founded in 2000, the company is known for its flagship product, NexoBrid, which is an FDA-approved biopharmaceutical designed for the removal of eschar in adults with deep partial- and full-thickness thermal burns, offering a less invasive alternative to surgical interventions. MediWound also advances other product candidates, including EscharEx, which has completed Phase II clinical trials for the debridement of chronic and hard-to-heal wounds, and MWPC003 for connective tissue disorders. The company aims to address significant unmet medical needs in these areas and improve patient outcomes.
Endoron Medical
Series A in 2024
Endoron Medical is a company focused on developing innovative medical devices aimed at enhancing the treatment of abdominal aortic aneurysms. The company specializes in creating an endovascular suture and a fixation device for endografts, which are essential for patients undergoing endovascular aneurysm repair. By employing advanced technology, Endoron Medical aims to provide long-lasting sealing solutions that improve patient outcomes and support healthcare professionals in effectively managing this serious condition.
Axelera AI
Series B in 2024
Axelera AI specializes in developing hardware and software platforms designed to accelerate artificial intelligence tasks, particularly for edge computing. Its flagship product, the Metis™ AI Platform, integrates both hardware and software components to deliver high-performance, energy-efficient AI inference solutions. The company is headquartered in Eindhoven with R&D offices in Belgium, Switzerland, and Italy.
Innatera develops ultra-low-power neuromorphic processors for sensors. Founded in 2018 as a spin-off from Delft University of Technology, the company designs neuromorphic chips that mimic brain mechanisms for processing sensory data. The processors use continuous-time analog-mixed signal computing to replicate spiking neurons and synapses, enabling sensor data to be processed faster and with substantially less energy than conventional processors.
UroMems is a medical device company dedicated to addressing specific clinical needs related to urinary conditions that significantly impact patients' quality of life. The company specializes in the design, development, and commercialization of active implantable medical devices. Its innovative approach aims to enhance existing surgical treatments by minimizing associated side effects and ensuring that patients receive appropriate care promptly. Through its commitment to improving treatment options, UroMems seeks to benefit a wide range of patients facing urinary health challenges.
iOnctura is a biopharmaceutical company specializing in the development of novel therapeutics aimed at addressing immunosuppression within the tumor microenvironment, which plays a significant role in cancer progression. The company seeks to enhance existing immune checkpoint therapies by creating new drugs that, when used in conjunction with these therapies, may improve safety and efficacy for cancer patients. iOnctura has formed strategic partnerships with prominent organizations, including Merck and Cancer Research Technology, to advance a pipeline of preclinical molecules toward clinical application. With access to advanced drug discovery labs and a network of academic collaborators, iOnctura is well-equipped to develop innovative combination therapies in the realm of cancer immunology, ultimately striving to optimize treatment outcomes for patients.
Qblox is a Dutch scaleup specializing in quantum technology, focused on developing patented solutions for the scalable control of quantum computers. The company designs and manufactures modular control hardware that simplifies the experimental setups involving qubits, employing a distributed processor architecture to enhance gate fidelities. By advancing electronics with improved noise and drift performance, Qblox enables scientists to minimize crosstalk and achieve low-latency arbitrary control flows while optimizing measurement efficiency in dynamic readout conditions. The company aims to address the scientific and engineering challenges that must be overcome to transition from prototype quantum computers to powerful, practical quantum processors.
Bank of Memories
Grant in 2024
Bank of Memories operates a digital platform for long-term preservation of personal data, enabling users to store and organize various forms of digital memories, such as photos, videos, and documents. The platform employs blockchain technology and decentralized storage to ensure data security and longevity, allowing individuals and families to pass on their memories across generations. It offers features like digital monuments for commemorative purposes and a dedicated data room for secure storage, along with an explorer tool for navigating stored information and a whitepaper detailing the platform's technology.
King's College London
Grant in 2024
King's College London is a public research university in London, United Kingdom, and a constituent college of the University of London. Founded in 1829 by King George IV and the Duke of Wellington, it operates from multiple central London campuses and a campus in Denmark Hill, with a strong emphasis on medical and biomedical research and education. The institution supports a large community of students and staff and is known for its extensive graduate and postgraduate programmes. It is a founding member of the King's Health Partners academic health sciences centre and participates in major research and academic networks, including the Russell Group and Universities UK.
Tilkal
Venture Round in 2024
Tilkal develops a software infrastructure that organizes traceability across various supply chain stakeholders. Founded in 2017, the company is headquartered in Paris, France.
ProFuse Technology
Grant in 2024
ProFuse Technology develops cultured meat production technology that accelerates muscle fiber growth, shortens production time, and increases yield and production capacity, with the aim of improving meat quality and consistency while reducing costs for producers by streamlining the manufacturing process and enabling higher-throughput production of cultured meat.
Riverlane is a developer of quantum computing software focused on transforming experimental technology into commercial products. The company engineers innovative instruments in collaboration with quantum computer manufacturers, addressing the need for new hardware and software tools to manage the instability of qubits and rectify system defects at unprecedented speeds. Riverlane's software includes an ultra-low latency quantum operating system that accelerates quantum-classical hybrid algorithms, supporting hardware research and development. Additionally, the company creates algorithms designed to optimize the use of the entire quantum computing stack, assisting hardware partners in minimizing the system errors that currently challenge quantum computing capabilities.
Vitestro develops autonomous blood drawing technology aimed at transforming patient care.
Vitestro develops autonomous blood drawing technology aimed at transforming patient care.
3deus Dynamics
Venture Round in 2024
3Deus Dynamics is a pioneering company specializing in advanced three-dimensional printing solutions. It has developed an innovative hybrid technology that combines elements of 3D printing and traditional injection molding, allowing for the processing of a wide range of polymers without the need for chemical reformulation. This technology eliminates the requirement for support structures and overcomes design geometry limitations, enabling the creation of complex products. The company's dynamic modeling capabilities enhance its manufacturing process by simulating composite materials, which facilitates the production of items tailored to specific functional properties. As a result, 3Deus Dynamics offers clients the flexibility to print a diverse array of products on demand, positioning itself at the forefront of the 3D printing industry.
Basemark specializes in developing augmented reality software for enhanced driver awareness and safety. It offers tools to avoid occlusion, prevent motion sickness, and support multiple in-vehicle displays, enabling automotive manufacturers to create practical AR applications.
BOYDSense
Venture Round in 2024
BOYDSense is a medical device company founded in 2015 and headquartered in South San Francisco, California. The company specializes in developing non-invasive and affordable tools for measuring critical biomarkers through exhaled breath. BOYDSense focuses on breath-based metabolomics, which involves capturing, identifying, and quantifying volatile organic compound (VOC) biomarker patterns found in human breath. This innovative approach enables medical professionals to simplify the monitoring, screening, and risk stratification of chronic diseases, facilitating more effective diagnosis and ongoing management of these conditions.
E-peas
Venture Round in 2024
E-peas SA is a Belgian company established in 2014, specializing in the design and manufacturing of electronic systems that provide energy autonomy for Internet of Things (IoT) applications. The company develops innovative energy harvesting solutions that enable devices to draw energy from various ambient sources, including solar, thermal, vibration, and radiofrequency. E-peas produces energy harvesting power management integrated circuits (PMICs) and microcontrollers that enhance the performance and longevity of IoT devices by either extending battery life or eliminating the need for batteries altogether. Their technology caters to a wide range of sectors, including home automation, healthcare, retail, and agriculture, thereby facilitating the creation of smarter and more energy-efficient connected devices. Headquartered in Mont-Saint-Guibert, Belgium, E-peas aims to transform the landscape of portable energy solutions.
Dronamics is a developer of advanced unmanned aerial systems aimed at transforming airfreight logistics. By creating a new type of small, unmanned cargo airplane that is highly fuel-efficient, Dronamics aims to democratize shipping in emerging markets. The aircraft can transport payloads of 350 kilograms over distances of 2,500 kilometers at costs significantly lower than traditional air transport, reducing shipping expenses by over 50%. Designed for autonomous flight, the aircraft can be remotely monitored and managed via satellite, making it suitable for challenging delivery scenarios, including remote and mountainous regions. As the first and only Strategic Partner for drones recognized by IATA, Dronamics is positioned to make a substantial impact in the commercial logistics sector.
RS Research is a clinical-stage biotechnology company focused on developing nanomedicines for cancer treatment. Based in Istanbul, Turkey, it has developed a proprietary Sagitta drug-delivery platform that enables targeted chemotherapies across multiple indications. The company advances a portfolio of nanomedicine candidates through preclinical and clinical stages, with its lead program RS-0139 studied in Phase I oncology trials and supported by a GMP-certified production facility for clinical batch drug candidates. RS Research collaborates with international partners on co-development projects and offers ancillary services such as preclinical absorption, distribution, metabolism, and excretion testing, bioanalytical method development and validation, impurity and metabolite analysis, stability testing, toxicology studies, and patent-related due diligence and drafting support. The business aims to deliver targeted therapies with improved therapeutic indices through its nanocarrier technology and partnerships.
Ability Pharmaceuticals
Venture Round in 2024
Ability Pharmaceuticals is a drug discovery and development company based in Barcelona, Spain. It develops human therapeutics targeting cell membranes to treat cancer and other indications with unmet medical needs.
Ability Pharmaceuticals is focused on developing new drugs for the treatment of lung cancer and pancreatic cancer. The company develops Lipid Analogue Therapeutics, a new drug class that modifies the composition of the cell membrane and displays a capacity to influence the local organization of lipid structures in the cell membrane, inducing the formation of non-lamellar phase structures.
Its development pipeline includes ABTL0812 product in preclinical development; and ABTL1014, a drug candidate in preclinical characterization.
Multiverse Computing
Series A in 2024
Founded in 2019 with headquarters in San Sebastian, Spain, Multiverse Computing develops quantum computing software tailored to solve complex real-world challenges. Its software leverages probabilistic technology for portfolio optimization, risk analysis, and market simulation, serving clients across industries such as finance, energy, manufacturing, and logistics.
Smart Farm Robotix
Grant in 2024
Smart Farm Robotix specializes in manufacturing agricultural robots that tackle the challenges of manual weeding, herbicide use, and machine weeding. Their robots provide a cost-effective, reliable, and fully automated solution, equipped with innovative weed detection and elimination technology. This enables farmers to cultivate crops more efficiently and sustainably, while reducing dependence on manual labor and harmful chemicals.
FreezeM is a company focused on advancing the use of insects as a sustainable protein source for the animal feed industry. Recognizing the potential of insects to address the growing demand for alternative protein, FreezeM develops innovative preservation technologies that facilitate large-scale freezing of insect species. This process aims to create a reliable supply of ready-to-use suspended neonates and frozen eggs, akin to agricultural seed production, which can overcome challenges related to availability, cost, and regulatory constraints. By establishing global stocks of beneficial insects, FreezeM supports various applications, including protein for animal feed, biological pest control, and species preservation, ultimately contributing to a more sustainable food system.
Daze is an engineering startup focused on creating innovative solutions for electric vehicle charging. Its flagship product, DazePlug, is an automatic charging device that utilizes smart charging ecosystems and energy management systems. This technology enables automatic inductive charging, significantly reducing the time required to charge electric vehicles while eliminating the need for manual handling of cables. DazePlug features a retrofit design that is both waterproof and dustproof, ensuring durability and ease of use. By simplifying the charging process, Daze aims to enhance user experience and convenience for electric vehicle owners.
Palobiofarma
Venture Round in 2024
Palobiofarma is a Spanish biotechnology company based in Barcelona’s Science Park, dedicated to discovering and developing innovative drugs that target adenosine receptors. The company aims to be the first European entity to bring an adenosine modulator to market, focusing on the treatment of diseases such as advanced prostate cancer. Through its expertise in medicinal chemistry and in vitro pharmacology, Palobiofarma is committed to advancing the understanding of adenosine's role in disease and enabling healthcare professionals to improve patient outcomes through novel therapeutic options.
Heart Aerospace
Series B in 2024
Heart Aerospace AB, established in 2018 with headquarters in Gothenburg, Sweden, and operations in Palo Alto, California, specializes in developing electric regional airliners certified for passenger flight. The company's mission is to facilitate swift, affordable, and sustainable travel for regional journeys worldwide. Their flagship aircraft, the ES-19, is a nineteen-passenger electric airliner designed with an operating range of 400 km, aiming to reduce fuel and maintenance costs compared to traditional aircraft while emitting zero operational emissions. Heart Aerospace targets commercial operation certification for the ES-19 by 2026.
Infinite Roots
Series B in 2024
Infinite Roots is a technology-driven company specializing in sustainable health and wellness products. They harness natural ingredients through fermentation technology to create organic, ethically sourced products like herbal supplements, skincare, and wellness solutions. The company's commitment lies in promoting holistic well-being while maintaining eco-friendly practices and ethical standards.
Brite Solar
Series A in 2024
Brite Solar is a nanomaterials company specializing in innovative solar glass technologies. Its primary product is transparent solar glass for greenhouses, enabling self-sufficient greenhouse operations and reducing carbon footprints by minimizing reliance on external energy sources. The company's technology, based on nano-materials ink-jet printed onto glass panels, also has applications in auto-dimming glass and architectural glass for buildings.
Aldoria specializes in space situational awareness services. It collects, processes, and uses data on space debris, satellites, and derelicts to monitor potential hazards and enable operators to adjust orbital routes, ensuring safety and sustainability in space.
QphoX
Venture Round in 2024
QphoX develops quantum modem devices that facilitate communication among quantum computers over a quantum network.
Wavess is an innovative predictive marketing analytics platform that uses advanced AI algorithms and behavioral science to forecast campaign success before launch. It primarily serves digital marketing agencies, scale-ups, and enterprises in fintech, retail, and technology sectors, providing insights into audience preferences for personalized marketing strategies.
Sentante
Seed Round in 2023
Sentante is a medical technology company specialising in the development of robotic teleoperated systems for endovascular procedures. Their core product enables physicians to perform complex surgeries remotely, reducing their exposure to harmful X-rays and expanding telesurgery capabilities.
NETRIS Pharma
Series A in 2023
NETRIS Pharma S.A.S. is a biotechnology company based in Lyon, France, focused on the identification and development of therapeutic molecules aimed at treating various forms of cancer. Established in 2008, the company specializes in targeting dependence receptors, which are trans-membrane proteins that play a crucial role in cellular signaling and tumor control. NETRIS Pharma conducts both in vitro and in vivo research, as well as preclinical practices, to manufacture drugs specifically for the treatment of breast cancer, lung cancer, glioblastoma, and neuroblastoma. Through its innovative approach, the company aims to advance cancer therapies and contribute to improved patient outcomes in the pharmaceutical industry.
Lotus Microsystems
Series A in 2023
Lotus Microsystems offers miniaturized highly integrated point of load power converters. The devices are engineered for portable electronics manufacturers ready for usage whenever tiny power supply units are needed. Our devices offer up to 72% reduction in footprint compared to existing solutions with higher efficiency and reliability. Our plug and play solutions enable our customers to innovate their electronics without worrying about power supply units.
Antabio is a private biopharmaceutical company based in Labege, France, focused on developing innovative treatments for drug-resistant infections, particularly targeting critical priority pathogens. Founded in 2009, the company specializes in creating novel antibacterial resistance-breakers, including stand-alone inhibitors of bacterial metalloenzymes. These inhibitors are designed to be combined with existing antibiotics, such as carbapenems, to restore their efficacy against the most challenging pathogens responsible for life-threatening infections, including carbapenem-resistant nosocomial pneumonia. Antabio aims to address significant unmet medical needs in the treatment of drug-resistant infections, ultimately providing healthcare professionals with effective medicinal products to combat these critical health challenges. The company has been recognized for its work, receiving a Wellcome Trust Seeding Drug Discovery Award.
Ignion
Venture Round in 2023
Founded in 2015, Ignion specializes in designing and manufacturing antennas tailored for mobile and wireless connectivity. Their off-the-shelf antennas cater to Internet of Things devices, mobile connectivity, and short-range wireless systems, facilitating seamless integration within industrial designs.
Quantum Diamonds
Seed Round in 2023
Quantum Diamonds specializes in the development of nitrogen-vacancy (NV) diamonds for quantum sensing applications. The company designs advanced quantum sensors capable of measuring magnetic fields, temperature, and pressure, offering enhanced sensitivity and resolution compared to traditional sensors. These sensors enable a range of applications, including navigation, bio-imaging, geographical surveying, and spectroscopy, even under challenging conditions. Quantum Diamonds focuses on optimizing performance in areas such as crystal lattice strain, Rabi contrast, and charge state stability, catering to both industrial and academic customers seeking innovative solutions in quantum mechanics.
RespiQ is a healthtech company developing portable, non-invasive breath analysis technology that uses emission spectroscopy and artificial intelligence to detect biomarkers in breath for early identification and real-time monitoring of respiratory diseases such as COPD, as well as other conditions like asthma, lung cancer, and infectious diseases. Its device aims to be affordable and user-friendly, democratizing access to advanced diagnostics, while its platform can also identify digestive issues through breath biomarkers and support personalized guidance via an app that analyzes a digital breath print to deliver diet and health insights, enabling individuals to monitor changes and improve health outcomes.
Efenco is a cleantech startup focused on enhancing the energy conversion efficiency of industrial furnaces and boilers while minimizing their carbon emissions. The company has developed a patented high-energy ray ceramic chip (HERC) that significantly reduces CO2 emissions and fuel costs by at least 18% in energy-intensive sectors, including electricity generation, steel manufacturing, pulp and paper production, ceramics, cement, and district heating. By leveraging principles from quantum and plasma physics, nanotechnology, and electrochemistry, Efenco's innovative technology captures and converts waste heat generated during natural gas combustion into a flux of ionizing radiation, thereby enabling industries to optimize energy usage and improve thermal conversion efficiency.
Methinks
Convertible Note in 2023
Methinks is a developer of a medical imaging platform that leverages advanced artificial intelligence techniques to enhance the diagnosis of brain-related diseases, particularly acute stroke. Utilizing Google's deep learning framework, Tensorflow, Methinks analyzes neuroimaging data to facilitate accurate and timely diagnoses. The platform offers a significant advantage by enabling stroke assessments through non-contrast CT scans, thereby eliminating the need for contrast CT and reducing the time required for treatment. This innovative approach enhances communication between radiologists, hospitals, stroke units, and other healthcare professionals, ultimately aiming to improve clinical outcomes in stroke care.
NEOGAP Therapeutics
Grant in 2023
NEOGAP Therapeutics is a clinical-stage biopharmaceutical startup focused on immuno oncology. Their pharmaceutical product, personalized tumor trained lymphocytes, offers even one customized cell treatment that is meant to precisely target and destroy cancer in a tailored environment, with very minor side effects.
Acorai develops a non-invasive heart failure monitoring platform centered around direct intracardiac pressure monitoring. Its patented technology combines sensor technologies and machine learning to enable accurate, cost-efficient care, reducing re-hospitalization and mortality rates.
Founded in 2014, Skytree develops direct air capture technology to recycle atmospheric CO2, providing a clean and reliable source for industries while contributing to global sustainability efforts.
Quandela is a company focused on advancing quantum computing technology, specifically in the realms of communication networks and optical computers. It specializes in manufacturing photonic quantum computers, which it supplies to industrial clients. A key innovation from Quandela is its single-photon source device, which integrates photonics with semiconductor quantum dots. This device enables the efficient collection of emitted single photons at high rates, significantly reducing charge noise decoherence and facilitating the emission of identical photons with high fidelity. Such capabilities are essential for the development of advanced quantum applications in communication, computation, and sensing, positioning Quandela as a pivotal player in the quantum technology landscape.
RAIKU Packaging
Grant in 2023
RAIKU is a cleantech startup that produces 100% natural packaging material that has also great looks and shock absorption - most importantly, it gives 15-20 times more volume to its raw material making it one of the most resource efficient material uses in the world with high margins. Both the production is and products are clean making no harm to nature.
RAIKU has raised over 1.2mln€ in the pre-seed stage, built a team of over 10 people, its own IP and clients are already using its packaging material. This material will up-end the 1 trillion € packaging sector.
ResoTher Pharma
Grant in 2023
ResoTher Pharma is a privately held biotechnology company based in Copenhagen, Denmark. The company specializes in developing peptide-based drugs derived from Annexin A1, an endogenous immunomodulator. These drugs are designed as resolution therapies for diseases where neutrophil-driven inflammation is a key pathological factor. ResoTher Pharma's primary focus is on addressing cardiovascular and inflammatory disorders that have significant unmet medical needs. Their patented peptide drugs target a G-protein coupled receptor expressed on leukocytes, aiming to mimic the body's natural response to resolving inflammation and promoting tissue repair.
Founded in 2017, SolasCure is a biotechnology company based in Wales, UK. It specializes in developing innovative hydrogel treatments for patients with chronic wounds. Its flagship product, Aurase, facilitates wound debridement, removing dead or infected tissue to enhance healing.
VSORA develops digital signal processing IP and chips for 5G networks, featuring a multicore DSP architecture that removes the need for DSP coprocessors and a shared DSP development flow that unites signal processing and software engineers in one environment to speed time-to-market. The company aims to boost DSP computing power while reducing power consumption, improving system performance, and shrinking silicon footprint. Based in France, founded in 2015 by veteran DSP engineers, VSORA serves chipmakers designing next-generation digital communications systems.